The current financial score of Cytokinetics Inc is 5.39. Its financial status is weak, and its operating efficiency is low. Its latest quarterly revenue reached 28.62M, representing a year-over-year decrease of 57.13%, while its net profit experienced a year-over-year decrease of 47.92%.
The current valuation score of Cytokinetics Inc is 9.42. Its current P/E ratio is -10.05, which is -51.78% below the recent high of -4.85 and -97.26% above the recent low of -19.82.
The current earnings forecast score of Cytokinetics Inc is 8.18. The average price target is 110.26, with a high of 146.00 and a low of 85.00.
The current price momentum score of Cytokinetics Inc is 4.08. Currently, the stock price is trading between the resistance level at 76.39 and the support level at 64.66, making it suitable for range-bound swing trading.
The current institutional shareholding score of Cytokinetics Inc is 10.00. The latest institutional shareholding proportion is 109.63%, representing a quarter-over-quarter decrease of 17.29%.
The current risk assessment score of Cytokinetics Inc is 7.78. The company's beta value is 0.41. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets.